ClinicalTrials.gg
Active, not recruitingNCT07055451Updated Aug 26, 2026

Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV

A Phase 1 interventional study of B/F/TAF in HIV-1-infection, sponsored by Gilead Sciences. Active, not recruiting at 7 sites in 2 countries. Open to participants aged Up to 120 Hours. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
Up to 120 Hours
Sex
All
01

Study summary

The goal of this clinical study is to learn more about the study drug, Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), safety, tolerability, and pharmacokinetics (how B/F/TAF is absorbed, modified, distributed, and removed from the body of the participants) in neonates exposed to human immunodeficiency virus type 1 (HIV-1).

The primary objective of this study is to evaluate the safety and plasma pharmacokinetics (PK) (how B/F/TAF is absorbed, modified, distributed, and removed from the body of the participants) of B/F/TAF tablet for oral suspension (TOS) in full-term neonates exposed to HIV-1 but uninfected.

02

Conditions studied

  • HIV-1-infection
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 120 Hours
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

Mother inclusion criteria:

  • Be on standard of care (SOC) antiretroviral therapy for type 1 (HIV-1) treatment.
  • Have confirmed HIV-1 infection based on positive test results obtained from medical records.

Neonate inclusion criteria:

  • Be born at term (≥ 37.0 weeks gestational age).
  • Be able to take oral medication.
  • Be ≤ 120 hours of life at enrollment.
  • Have a birth weight ≥ 2.5 kg.
  • Is receiving or plans to receive HIV-1 SOC prophylaxis regimen with 1 antiretroviral (ARV) to prevent perinatal transmission.

Key Exclusion Criteria:

Mother exclusion criteria:

  • Has a maternal-fetal blood group incompatibility identified by antibody that can cause hemolytic diseases of the neonate.
  • Is breastfeeding or plans to breastfeed while on bictegravir (BIC) or emtricitabine (FTC) containing regimen. Mothers on BIC or FTC containing regimen, but not breastfeeding, can be enrolled in the study.

Neonate exclusion criteria:

  • Had prior or expected to require blood exchange transfusion.
  • Is receiving or plans to receive any component of B/F/TAF or dolutegravir as part of their SOC ARV prophylaxis regimen.
  • Has a documented positive HIV-1 nucleic acid test.
  • Has Grade 2 or higher , total , , or creatinine. Has Grade 1 or higher alanine aminotransferase.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Cohort 1: Group A of B/F/TAF

    Full-term neonate participants, who are exposed to HIV-1 but uninfected, with a weight of ≥ 2.5 kg at birth and their mothers will be assigned to Cohort 1 Group A to evaluate a different pharmacokinetic (PK) sampling scheme than Cohort 1 Group B. Neonate participants will receive a single dose of B/F/TAF fixed-dose combination 1.88/7.5/0.94 mg tablet for oral suspension administered along with 1 antiretroviral as standard of care postnatal prophylaxis at both Visits 1 and 3.

    Drug: B/F/TAF

  • Experimental
    Cohort 1: Group B of B/F/TAF

    Once enrollment in Cohort 1 Group A is completed, full-term neonate participants, who are exposed to HIV-1 but uninfected, with a weight of ≥ 2.5 kg at birth and their mothers will be assigned to Cohort 1 Group B to evaluate a different PK sampling scheme than Cohort 1 Group A. Participants will receive a single dose of B/F/TAF fixed-dose combination 1.88/7.5/0.94 mg tablet for oral suspension administered along with 1 antiretroviral as standard of care postnatal prophylaxis at both Visits 1 and 3.

    Drug: B/F/TAF

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAs) Though Week 8 After Neonate Birth

    Time frame: First dose date up to 8 Weeks

  2. Percentage of Participants Experiencing Treatment-emergent Laboratory Abnormalities Through Week 8 After Neonate Birth

    Time frame: First dose date up to 8 Weeks

  3. Pharmacokinetic (PK) parameters for Bictegravir (BIC): AUCinf

    AUCinf is defined as area under the concentration versus time curve extrapolated to infinite time.

    Time frame: Predose up to 72 hours postdose

  4. PK parameters for BIC: AUClast

    AUClast is defined as the area under the concentration versus time curve from time zero to the last quantifiable concentration.

    Time frame: Predose up to 72 hours postdose

  5. PK parameters for BIC: AUC0-24h

    AUC0-24h is defined as the partial area under the concentration versus time curve from time 0 to time 24 hours.

    Time frame: Predose up to 24 hours postdose

  6. PK parameters for BIC: Cmax

    Cmax is defined as the maximum observed concentration of drug.

    Time frame: Predose up to 72 hours postdose

  7. PK parameters for BIC: Tmax

    Tmax is defined as the time (observed time point) of Cmax.

    Time frame: Predose up to 72 hours postdose

  8. PK parameters for BIC: Cmin

    Cmin is defined as the minimum observed concentration of drug.

    Time frame: Predose up to 72 hours postdose

  9. PK parameters for BIC: C24h

    C24h is defined as the concentration of drug at time 24 hours.

    Time frame: At 24 hours postdose

  10. PK parameters for BIC: t1/2

    t1/2 is defined as the terminal elimination half-life.

    Time frame: Predose up to 72 hours postdose

  11. PK parameters for BIC: Apparent CL/F

    Apparent CL/F is defined as the apparent total body clearance for extravascular administration.

    Time frame: Predose up to 72 hours postdose

  12. PK parameters for BIC: Apparent Vz/F

    Apparent Vz/F is defined as the apparent volume of distribution based on the terminal phase.

    Time frame: Predose up to 72 hours postdose

Secondary outcomes

  1. PK Parameters for Emtricitabine (FTC), and Tenofovir (TFV): AUCinf

    AUCinf is defined as the area under the concentration versus time curve extrapolated to infinite time.

    Time frame: Predose up to 72 hours postdose

  2. PK parameters for FTC, TAF, and TFV: AUClast

    AUClast is defined as the area under the concentration versus time curve from time zero to the last quantifiable concentration.

    Time frame: Predose up to 72 hours postdose

  3. PK parameters for FTC, TAF, and TFV: AUC0-24h

    AUC0-24h is defined as the partial area under the concentration versus time curve from time 0 to time 24 hours.

    Time frame: Predose up to 24 hours postdose

  4. PK parameters for FTC, TAF, and TFV: Cmax

    Cmax is defined as the maximum observed concentration of drug.

    Time frame: Predose up to 72 hours postdose

  5. PK parameters for FTC, TAF, and TFV: Tmax

    Tmax is defined as the time (observed time point) of Cmax.

    Time frame: Predose up to 72 hours postdose

  6. PK parameters for FTC, TAF, and TFV: Cmin

    Cmin is defined as the minimum observed concentration of drug.

    Time frame: Predose up to 72 hours postdose

  7. PK parameters for FTC, TAF, and TFV: C24h

    C24h is defined as the concentration of drug at time 24 hours.

    Time frame: At 24 hours postdose

  8. PK parameters for FTC, TAF, and TFV: t1/2

    t1/2 is defined as the terminal elimination half-life.

    Time frame: Predose up to 72 hours postdose

  9. PK parameters for FTC and TAF: Apparent CL/F

    Apparent CL/F is defined as the apparent total body clearance for extravascular administration.

    Time frame: Predose up to 72 hours postdose

  10. PK parameters for FTC and TAF: Apparent Vz/F

    Apparent Vz/F is defined as the apparent volume of distribution based on the terminal phase.

    Time frame: Predose up to 72 hours postdose

  11. Mother/Caregiver Reported Acceptability of B/F/TAF tablet for oral suspension (TOS)

    Acceptability assessed by a numeric response between numbers 1-5. Higher scores indicate better acceptability.

    Time frame: First dose date up to 15 days

  12. Mother/Caregiver Reported Palatability of B/F/TAF tablet for oral suspension (TOS)

    Palatability assessed by a numeric response between numbers 1-5. Higher scores indicate better palatability.

    Time frame: First dose date up to 15 days

07

Study locations

7 sites
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Mar 2028, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2025
First posted
Jul 9, 2025
StartActual
Aug 12, 2025
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2028
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07055451
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jul 9, 2025
Start date
Aug 12, 2025
Primary completion
Mar 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Aug 26, 2026

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bictegravir · Emtricitabine · Tenofovir alafenamide

Start the discussion